Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good article
"On June 6, 2013, the company announced the blinded results from the first of two placebo-controlled double blind studies in volunteers using RXI-109. Almost three months after a single intradermal dose of the drug, histological comparisons showed significantly reduced expressions of CTGF in the wound area in a dose dependent manner, reducing abnormal scarring.
The success confirms the efficacy of its sd-rxRNA® platform, which could solve drug delivery issues that have plagued the industry. Instead of simply encapsulating RNAi into a lipid-based particular, the company’s innovative technology reduces the need for any delivery technology by building drug-like properties into the RNAi compound itself.
The sd-rxRNA® platform is ideal for therapeutic use and have drug-like properties like high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. Researchers and investors may want to keep an eye on the firm’s upcoming trials, as they could confirm safety and efficacy and set the stage for additional therapeutics."
http://investor.biospace.com/biospace/news/read/24515183/rnai_therapeutics_make_progress_across_the_board
Excerpts from the OTCQX website:
"Who Should Join OTCQX
Many U.S. companies join OTCQX as the final step toward a NASDAQ or NYSE listing. Others enjoy the efficient compliance-driven and cost-effective model it offers their investors outside of a traditional exchange listing...
Why Investors Prefer OTCQX
OTCQX separates out the credible companies from the large number of economically distressed and questionable companies that trade OTC. Companies that join OTCQX demonstrate their commitment to providing superior information to investors and maintaining the highest quality standards. "
http://www.otcqx.com/qx/otcqx/overview
Geert Cauwenbergh is the man!
GLTA!
Thanks trading.jeff
Are there any milestones coming up this month?
Looks like 2013 is the year we push the throttle. Good luck to all patient longs and people newly into Actc.
Hope everyone had a great Memorial Day weekend!
Not sure why the pps didn't rise as much though. Is it because the improvement was only for one patient? I personally thought the news was big enough for the pps to hover close to .09-.10 at least. Maybe if it had been released through a news conference with some additional items instead of being leaked inadvertently, we would have seen such a run.
Thanks for sharing the video chuckanutman. People who doubt the science and the company should really ask themselves why such prestigious eye institutes in the country would get involved in trying a phase I treatment on only a handful of patients if they didn't see any promise and substance in the company's work so far. GLTA who've been patiently invested in this amazing company.
I hope we RS at a ratio of less than 10 to 1. Go ACTC!
There are 9 major milestones this year - 6 clinical milestones and 3 interim data. Hope we get to hear some good news tomorrow that marks the beginning of OncoSec's good times. GLTA!
This looks great - thanks for the links!
That makes sense lasers. I hope that's what they're aiming for.
Does this slip up and subsequent confirmation put pressure on ACT to release further data which they might already have earlier than planned?
Just a thought...
I think something big is brewing in the labs of ACT. Otherwise, I don't see the point in wanting to do a RS to uplist. There has to be some news to sustain a new share price at $4 - $5. If they're serious about a RS this year, then it should be accompanied by news of a decent magnitude. What do you guys think?
Punit Dhillon and OncoSec featured in a news article
VC Climate in Canada Still Chilly for Biotechs
I'm guessing this article was responsible for today's pps action.
I agree with you art2426. Plus the pps hasn't dropped below 7 cents which is a clear indication that the market has already digested the news about Rabin and that we shouldn't be worried about this.
Seeking Alpha article on ONCS
ONCS currently has approximately $9m in cash after recently completing a $7.3m financing. Over the last year ONCS has averaged an approximate quarterly cash burn of $1.4m. With the recent financing the company appears to be fully funded for the next several quarters. Given the six clinical trials ongoing this cash burn appears to be relatively low compared to other biotech stocks I have researched, a positive for investors as it reduces the risk of dilution. ONCS has a market cap that is under $30m with two cancer drugs already in Phase III trials. In comparison, VICL is trading with a market cap of $340m.
Like all bio stocks ONCS carries risk: Risk that the trials will fail down the road and risk of dilution. But I will also say that with that risk the rewards, if the trials are successful, can be very nice. With an extremely low market valuation and two Phase III cancer trials ongoing, the stock appears cheap. If the Phase III results do not come out positive then the stock could see a return to its lows. However, given the strong results already seen in the current trials that risk seems greatly diminished.
Doesn't seem implausible reading this stock coverage initiation report from November 2012: LifeSci Advisors
New intro video at OncoSec.com
Did everyone check out the video with Punit Dhillon? The prospects of this company look very encouraging to me. If I had to pick three speculative investments with the best potential, ONCS would definitely be one of them.
OncoSec Collaborates with Smart Patients to Form New Online Community for Patients
Extract from Yahoo Finance:
"OncoSec Medical Inc. (ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, is one of the first to partner with Smart Patients: a new online community where patients with life-threatening conditions who are looking for or participating in clinical trials can share their feedback and experiences. Google’s former Chief Health Strategist, Roni Zeiger, will be speaking at the TEDMED conference in Washington, D.C. today to unveil the new website.
OncoSec is working with Smart Patients to create a community for Merkel cell carcinoma (MCC) patients. MCC is an extremely rare and aggressive form of skin cancer that currently has no approved therapies. OncoSec is conducting the only active Phase II immunotherapy trial that is focused specifically on the disease. The Smart Patients partnership will provide valuable insight from patients to help improve clinical trial design and enable better collaboration with patients."
Full Article
A collection of expert analysis on ONCS...This might have made it to this board in the past already but might be of interest to people new to the company.
The Life Sciences Report
Very excited about this stock. Tripled my holdings recently. Is July going to be the month when we start getting results on the catalysts?
I got RXII shares through GALE...thought about adding more when it was .07, but didn't..thought again at .15 but alas, didn't do it..I finally loaded up at .26..hoping it follows a similar trajectory as GALE did..good luck to everyone!
Which will come first - RS annoucement for 2013 or some big news similar to what came in Jan 2012? Any guesses?
Is 2013 RS ratio still likely to be within the same range as declared for 2012?
Is a reverse split inevitable in the near future?
What kind of news would be required to push the pps to $5 without a R/S?
What is that pps you think is a deal too good to pass to hoard more ACTC stock despite the upcoming RS? .5? .6?
After the decision to do the RS was announced, I believe there hasn't been any news on the research and treatment front of ACTC that ought to be driving the pps this down. Is it just the idea of the split that is doing this?
I'm pretty sure that GR and team have some big news cooking in the lab that gave them enough confidence to declare a RS. I believe they are sincere in their desire to take ACTC to NASDAQ. To be honest, I haven't added any shares after the RS news but I am looking for a good bargain. Any thoughts folks?
Good for you BDaddy! I got in at .92. After a month or so, there was a period when it hovered around .38-.40. I considered increasing my stake in the stock at that time but eventually refrained from doing so thinking the stock might tank further. You can tell how much I regret it now. Anyhoo, no use crying over spilt opportunity to buy more of a cheap stock with huge upside. Go GALE! Good luck to all on board!
GTRman, I like your analogy with Bill Gates and Steve Jobs. I'll add Mark Zuckerberg and Facebook. They have proved that big things can start from the vision, talent and business acumen of a single person. I think Dr. Lanza is one of those people who will create something new for this world.
I am not going to care about ACT's earnings releases for a couple of years. I believe we have something big coming up in the near future.
Article from Seeking Alpha
"A Paradigm Shift Without A Clutch"
http://seekingalpha.com/article/392111-a-paradigm-shift-without-a-clutch?source=yahoo
Happy reading!
Exxon Mobil (XOM) has 4.79B shares outstanding. MSFT has 8.3B. But they are in their own league.
Elysse I did mean double digit dollars lol..You are right, you do have to learn to crawl before you learn to walk. You see, I am always wondering what's the right amount of this stock I should buy and hold. Currently I hold less than 50K shares. I just don't want to be holding too little of this stock when that day comes. You can easily tell I'm new to investing. But hey, I hope a little day dreaming doesn't hurt when you're investing in a company that's expected to change the field of medicine if its science works :)
What would be your estimate of ACTC stock price range if
their science does work and they get FDA approval to cure AMD? Let's say this happens in 2-5 years. Where do you think the stock price will range? It will def. be double digits but do you think it can go past that? Let's hear everyone's thoughts.
Crawford, I couldn't agree more with you. I see 2012 as a last chance to get into this stock cheaply. I don't think it is going to remain a penny stock for long. ACTC!
I totally agree with sports guy. This may well be the best time to get in ACTC. I hope ACTC to be not just a portfolio changing stock but a life changing one.
Warren Buffet once said, "Be fearful when others are greedy and greedy when others are fearful." Now is the time to be to greedy IMO when people still have doubts about the science of stem cells. Not saying that I'm 100% confident that the science will prevail, but hey, if I were to risk some capital on any one of the many biotech/biopharmaceutical stocks out there today, I'd be most comfortable risking it on ACT due to the results of the latest study.
Good luck to ACT, it's study patients, and to us all!
Rocky, thanks for the clarification and also for the link.
Why do none of the articles that I've read online on the study's results mention that ACT derives the stem cells without destroying embryos? I think if it were, it would generate a lot more interest in the company and its work (and more importantly, its stock!)